Cargando…

Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states

Mostrar otras versiones (1)

Clear cell renal cell carcinoma (ccRCC) is molecularly heterogeneous, immune infiltrated, and selectively sensitive to immune checkpoint inhibition (ICI). Established histopathology paradigms like nuclear grade have baseline prognostic relevance for ccRCC, although whether existing or novel histolog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nyman, Jackson, Denize, Thomas, Bakouny, Ziad, Labaki, Chris, Titchen, Breanna M., Bi, Kevin, Hari, Surya Narayanan, Rosenthal, Jacob, Mehta, Nicita, Jiang, Bowen, Sharma, Bijaya, Felt, Kristen, Umeton, Renato, Braun, David A., Rodig, Scott, Choueiri, Toni K., Signoretti, Sabina, Van Allen, Eliezer M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882334/ https://www.ncbi.nlm.nih.gov/pubmed/36712053 http://dx.doi.org/10.1101/2023.01.18.524545

Ejemplares similares

Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states
por: Nyman, Jackson, et al.
Publicado: (2023)

Recovery of cancer screening tests and possible associated disparities after the first peak of the COVID-19 pandemic
por: Labaki, Chris, et al.
Publicado: (2021)

Characterization of the Cellular Origin and Oncogenic Mechanisms of Chromophobe Renal Cell Carcinoma (ChRCC) and Renal Oncocytic Neoplasms
por: Labaki, Chris, et al.
Publicado: (2023)

Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology
por: Rosenthal, Jacob, et al.
Publicado: (2022)

Computed Tomography Texture Analysis for Predicting Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors
por: Park, Hyo Jung, et al.
Publicado: (2022)

Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinoma
por: Saliby, Renee Maria, et al.
Publicado: (2023)

Integrative Analysis of Germline Rare Variants in Clear and Non-Clear Cell Renal Cell Carcinoma
por: Han, Seunghun, et al.
Publicado: (2023)

Host immune signatures as predictors of response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC)
por: Saad, Eddy, et al.
Publicado: (2023)

Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset
por: Kehl, Kenneth L., et al.
Publicado: (2021)

Epigenomic profiling nominates master transcription factors (TFs) driving sarcomatoid differentiation (SD) of renal cell carcinoma (RCC)
por: El Zarif, Talal, et al.
Publicado: (2023)

In Reply
por: de Velasco, Guillermo, et al.
Publicado: (2017)

COVID-19 and Cancer: Current Challenges and Perspectives
por: Bakouny, Ziad, et al.
Publicado: (2020)

Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
por: Bi, Kevin, et al.
Publicado: (2021)

First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape
por: Gulati, Shuchi, et al.
Publicado: (2022)

Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma
por: Mullane, Stephanie A., et al.
Publicado: (2016)

NF-κB-regulated VentX expression mediates tumoricidal effects of chemotherapeutics at noncytotoxic concentrations
por: Le, Yi, et al.
Publicado: (2022)

Differences in Kinematic Changes From Self-Selected to Fast Speed Gait in Asymptomatic Adults With Radiological Signs of Femoro-Acetabular Impingement
por: Yared, Fares, et al.
Publicado: (2023)

Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway
por: Stransky, Laura A., et al.
Publicado: (2022)

Identification of ALK Gene Alterations in Urothelial Carcinoma
por: Bellmunt, Joaquim, et al.
Publicado: (2014)

Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases
por: Schoenfeld, David A, et al.
Publicado: (2023)

Public Reporting of Quality Information on Medicaid Health Plans
por: Felt-Lisk, Suzanne, et al.
Publicado: (2007)

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2021)

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2021)

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma
por: Hamieh, Lana, et al.
Publicado: (2018)

Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial
por: Choueiri, Toni K., et al.
Publicado: (2020)

Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer
por: Alessi, Joao V, et al.
Publicado: (2021)

Landscape of tumor-infiltrating T cell repertoire of human cancers
por: Li, Bo, et al.
Publicado: (2016)

Metabolomic adaptations and correlates of survival to immune checkpoint blockade
por: Li, Haoxin, et al.
Publicado: (2019)

Survey of the Impact of COVID-19 on Oncologists’ Decision Making in Cancer
por: Ürün, Yüksel, et al.
Publicado: (2020)

Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas
por: Alhalabi, Omar, et al.
Publicado: (2023)

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2022)

Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
por: Li, Bo, et al.
Publicado: (2016)

Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma
por: Deutsch, Julie Stein, et al.
Publicado: (2023)

502P Association of immunotherapy and immunosuppression with severe COVID-19 disease in patients with cancer
por: Bakouny, Z., et al.
Publicado: (2022)

Habitat Suitability and Conflict Zone Mapping for the Blue Bull (Boselaphus tragocamelus) across Nepal
por: Dhami, Bijaya, et al.
Publicado: (2023)

Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression
por: Lalani, Aly-Khan A., et al.
Publicado: (2017)

A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma
por: Nassar, Amin H., et al.
Publicado: (2019)

Genomic investigation of etiologic heterogeneity: methodologic challenges
por: Begg, Colin B, et al.
Publicado: (2014)

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
por: Miao, Diana, et al.
Publicado: (2018)

Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma
por: Abou Alaiwi, Sarah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g52s2jf4tb2mdb5hj5q9t4h9pr